2013
DOI: 10.1111/avj.12080
|View full text |Cite|
|
Sign up to set email alerts
|

Bioequivalence of a new liquid formulation of benazepril compared with the reference tablet product

Abstract: This study supports a conclusion that, based on pharmacodynamic response, the liquid formulation of benazepril is bioequivalent to the reference tablet formulation. Further, the lack of a sequence effect supports the switchability of these two formulations.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2013
2013
2022
2022

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 7 publications
0
1
0
Order By: Relevance
“…A bioequivalence study compared the currently approved tablet formulation of the angiotensin‐converting enzyme (ACE) inhibitor, benazepril, with an investigational liquid formulation to determine if the bioavailability, efficacy and safety of the two formulations were comparable …”
Section: Small Animalsmentioning
confidence: 99%
“…A bioequivalence study compared the currently approved tablet formulation of the angiotensin‐converting enzyme (ACE) inhibitor, benazepril, with an investigational liquid formulation to determine if the bioavailability, efficacy and safety of the two formulations were comparable …”
Section: Small Animalsmentioning
confidence: 99%